PROVEN TO CURE
HEP C PATIENTS LIKE YOU
In a clinical study, VOSEVI was shown to have high cure rates in patients with Hep C genotype 1, 2, 3, 4, 5, or 6, without cirrhosis or with compensated cirrhosis,* who had been previously treated with certain advanced Hep C regimens.† Cure means the Hep C virus is not detected in the blood when measured three months after treatment is completed.
VOSEVI is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C (Hep C) genotype 1, 2, 3, 4, 5, or 6 infection with or without cirrhosis (compensated) who have previously been treated with a Hep C regimen containing an NS5A inhibitor.
Genotype 1, 2, 3, 4, 5, or 6 Patients
12 Weeks of Treatment |
| Genotype |
Dosing |
Cure Rates‡ |
| 1 |
One Pill per Day
With Food |
97% |
| 2 |
100% |
| 3 |
95% |
| 4 |
91% |
| 5 |
100% |
| 6 |
100% |
*Compensated cirrhosis is a type of advanced liver disease in which healthy liver tissue is replaced with scar tissue, but the liver is still able to carry out its important functions.
†A Hep C regimen containing an NS5A inhibitor, including EPCLUSA®, HARVONI®, Viekira Pak®, Viekira XR®, Technivie®, Zepatier®, and regimens containing Daklinza®.
‡In a study of 263 patients with genotype 1, 2, 3, 4, 5, or 6 Hep C, without cirrhosis or with compensated cirrhosis, who previously failed a Hep C regimen containing an NS5A inhibitor, 97% (146 out of 150) of patients with genotype 1, 100% (5 out of 5) of patients with genotype 2, 95% (74 out of 78) of patients with genotype 3, 91% (20 out of 22) of patients with genotype 4, 100% (1 out of 1) of patients with genotype 5, and 100% (6 out of 6) of patients with genotype 6 who received VOSEVI once daily for 12 weeks were cured.
LEARN ABOUT COMMON SIDE EFFECTS WITH VOSEVI
VOSEVI is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C (Hep C) genotype 1, 2, 3, 4, 5, or 6 infection with or without cirrhosis (compensated) who have previously been treated with a Hep C regimen containing an NS5A inhibitor.
Important Safety Information
What is the most important information I should know about VOSEVI?
VOSEVI can cause serious side effects, including:
- Hepatitis B virus reactivation: Before starting VOSEVI treatment, your healthcare provider will do blood tests to check for hepatitis B infection. If you have ever had hepatitis B, the hepatitis B virus could become active again during or after treatment with VOSEVI. This may cause serious liver problems including liver failure and death. If you are at risk, your healthcare provider will monitor you during treatment and after you stop taking VOSEVI.
Who should not take VOSEVI?
- Do not take VOSEVI if you take medicines that contain rifampin (Rifater®, Rifamate®, Rimactane®, Rifadin®).
What should I tell my healthcare provider before taking VOSEVI?
- Tell your healthcare provider about all of your medical conditions, including if you have ever had hepatitis B infection or liver problems other than hepatitis C infection; if you have severe kidney problems or are on dialysis; or if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed. It is not known if VOSEVI will harm your unborn baby or pass into your breast milk.
- Tell your healthcare provider and pharmacist about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VOSEVI and certain other medicines may affect each other, or may cause side effects.
Continued below